Subcutaneous; SRE: Skeletal-related event; SSE: Symptomatic skeletal event; Z4: Zoledronic acid 4 mg every 3 weeks; Z8: Zoledronic acid 8 mg every 3 weeks. Androgen deprivation is the mainstay of ...

Gnant, M. et al.Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol ...

Subcutaneous; SRE: Skeletal-related event; SSE: Symptomatic skeletal event; Z4: Zoledronic acid 4 mg every 3 weeks; Z8: Zoledronic acid 8 mg every 3 weeks. Androgen deprivation is the mainstay of ...